PreproNPY Pro7 protects against depression despite exposure to environmental risk factors

Journal of Affective Disorders

Volumn 118, Issue 1-3, 2009, Pages 124-130

  Sjöholm, Louise K ^a   Melas, Philippe A ^a   Forsell, Yvonne ^a   Lavebratt, Catharina ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Anxiety; Leu Pro; Leu7Pro; Major depression; Neuropeptide Y

Indexed keywords

LEUCINE; NEUROPEPTIDE Y DERIVATIVE; PREPRONEUROPEPTIDE Y; PROLINE; SIGNAL PEPTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DEPRESSION; ENVIRONMENTAL EXPOSURE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; RISK FACTOR; SWEDEN;

ADULT; ALLELES; ANXIETY DISORDERS; DEPRESSIVE DISORDER; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HETEROZYGOTE DETECTION; HOMOZYGOTE; HUMANS; LIFE CHANGE EVENTS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROPEPTIDE Y; POLYMORPHISM, GENETIC; PROTEIN PRECURSORS; RISK FACTORS; SOCIAL ENVIRONMENT; SWEDEN; YOUNG ADULT;

EID: 69949165879     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jad.2009.02.009     Document Type: Article

References (55)

1. Bech P., and Wermuth L. Applicability and validity of the Major Depression Inventory in patients with Parkinson's disease. Nord. J. Psychiatry. 52 (2000) 305-309
2. Beglin S.J., and Fairburn C.G. Evaluation of a new instrument for the detection of eating disorders in community samples. Psychiatry Res. 44 (1992) 191-201
3. Bergman P.N., Ahlberg G., Forsell Y., Lundberg I., Non-participation in the second wave of the PART study on mental disorder and its effects on risk Estimates. Psychiatry Res. In press.
4. Brugha T.S. Social support and psychiatric disorder: overview of evidence. In: Brugha T.S. (Ed). Social Support and Psychiatric Disorder: Research Findings and Guidelines for Clinical Practice (1995), Cambridge University Press, Cambridge 1-40
5. Caberlotto L., and Hurd Y.L. Reduced neuropeptide Y mRNA expression in the prefrontal cortex of subjects with bipolar disorder. Neuroreport 10 (1999) 1747-1750
6. Ding B. Distribution of the NPY 1128C allele frequency in different populations. J. Neural Transm. 110 (2003) 1199-1204
7. Goodman W.K., Price L.H., Rasmussen S.A., Mazure C., Delgado P., Heninger G.R., and Charney D.S. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch. Gen. Psychiatry. 46 (1989) 1012-1016
8. Gustavsson J.P.H., Bergman G., Edman L., Ekselius L., and von Knorring Linder J. Swedish Universities Scales of Personality (SSP): construction, internal consistency and normative data. Acta Psychiatr. Scand. 102 (2000) 217-225
9. Heilig M. The NPY system in stress, anxiety and depression. Neuropeptides 38 (2004) 213-224
10. Heilig M., Zachrisson O., Thorsell A., Ehnvall A., Mottagui-Tabar S., Sjögren M., Asberg M., Ekman R., Wahlestedt C., and Agren H. Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar major depression: preliminary evidence for association with preproNPY gene polymorphism. J. Psychiatr. Res. 38 (2004) 113-121
11. Hällström T., Damström-Thakker K., Forsell Y., Lundberg I., and Tinghög P. The Part study. A population based study of mental health in the Stockholm county: study design (2003). http://www.folkhalsoguiden.se/upload/Psykisk http://www.folkhalsoguiden.se/upload/Psykisk%20H%c3%a4lsa/PARTs%20tekniska%20rapport.pdf
12. Ilveskoski E., Viiri L.E., Mikkelsson J., Pörsti I., Lehtimäki T., and Karhunen P.J. Neuropeptide Y signal peptide Pro7 substitution protects against coronary artery atherosclerosis: the Helsinki Sudden Death Study. Atherosclerosis 199 (2007) 445-450
13. Ishida H., Shirayama Y., Iwata M., Katayama S., Yamamoto A., Kawahara R., and Nakagome K. Infusion of neuropeptide Y into CA3 region of hippocampus produces antidepressant-like effect via Y1 receptor. Hippocampus 17 (2007) 271-280
14. Jaakkola U., Kallio J., Heine R.J., Nijpels G., Hart L.M., Maassen J.A., Bouter L.M., Stehouwer C.D., and Dekker J.M. Neuropeptide Y polymorphism significantly magnifies diabetes and cardiovascular disease risk in obesity: the Hoorn Study. Eur. J. Clin. Nutr. (2007) Nov 28
15. Janca A., Kastrup M., Katschnig H., López-Ibor Jr. J.J., Mezzich J.E., and Sartorius N. The World Health Organization Short Disability Assessment Schedule (WHO DAS-S): a tool for the assessment of difficulties in selected areas of functioning of patients with mental disorders. Soc. Psychiatry Psychiatr. Epidemiol. 31 (1996) 349-354
16. Jiménez Vasquez P.A., Salmi P., Ahlenius S., and Mathé A.A. Neuropeptide Y in brains of the Flinders Sensitive Line rat, a model of depression. Effects of electroconvulsive stimuli and d-amphetamine on peptide concentrations and locomotion. Behav. Brain Res. 111 (2000) 115-123
17. Jiménez-Vasquez P.A., Mathé A.A., Thomas J.D., Riley E.P., and Ehlers C.L. Early maternal separation alters neuropeptide Y concentrations in selected brain regions in adult rats. Brain Res. Dev. Brain Res. 2131 (2001) 149-152
18. Jiménez-Vasquez P.A., Diaz-Cabiale Z., Caberlotto L., Bellido I., Overstreet D., Fuxe K., and Mathé A.A. Electroconvulsive stimuli selectively affect behavior and neuropeptide Y (NPY) and NPY Y(1) receptor gene expressions in hippocampus and hypothalamus of Flinders Sensitive Line rat model of depression. Eur. Neuropsychopharmacol. 17 (2007) 298-308
19. Kallio J., Pesonen U., Kaipio K., et al. Altered intracellular processing and release of neuropeptide Y due to leucine 7 to proline 7 polymorphism in the signal peptide of preproneuropeptide Y in humans. FASEB J. 15 (2001) 1242-1244
20. Karl T., and Herzog H. Behavioral profiling of NPY in aggression and neuropsychiatric diseases. Peptides 28 (2007) 326-333
21. Karlsson R.M., Choe J.S., Cameron H.A., Thorsell A., Crawley J.N., Holmes A., and Heilig M. The neuropeptide Y Y1 receptor subtype is necessary for the anxiolytic-like effects of neuropeptide Y, but not the antidepressant-like effects of fluoxetine, in mice. Psychopharmacol 195 (2008) 547-557
22. Karvonen M.K., Pesonen U., Koulu M., et al. Association of a leucine(7)-to-proline(7) polymorphism in the signal peptide of neuropeptide Y with high serum cholesterol and LDL cholesterol levels. Nat. Med. 4 (1998) 1434-1437
23. Karvonen M.K., Koulu M., Pesonen U., et al. Leucine 7 to proline 7 polymorphism in the preproneuropeptide Y is associated with birth weight and serum triglyceride concentration in preschool aged children. J. Clin. Endocrinol. Metab. 85 (2000) 1455-1460
24. Karvonen M.K., Valkonen V.P., Lakka T.A., et al. Leucine7 to proline7 polymorphism in the preproneuropeptide Y is associated with the progression of carotid atherosclerosis, blood pressure and serum lipids in Finnish men. Atherosclerosis 159 (2001) 145-151
25. Karvonen M.K., Ruottinen S., Koulu M., et al. Nutrient intake, weight, and Leu7Pro polymorphism in prepro-neuropeptide Y in children. J. Clin. Endocrinol. Metab. 91 (2006) 4664-4668
26. Kauhanen J., Karvonen M.K., Pesonen U., Koulu M., Tuomainen T.P., Uusitupa M.I., and Salonen J.T. Neuropeptide Y polymorphism and alcohol consumption in middle-aged men. Am. J. Med. Genet. 93 (2000) 117-121
27. Kendler K.S., Gardner C.O., and Prescott C.A. Toward a comprehensive developmental model for major depression in women. Am. J. Psychiatry 159 (2002) 1133-1145
28. Kendler K.S., Gardner C.O., and Prescott C.A. Toward a comprehensive developmental model for major depression in men. Am. J. Psychiatry 163 (2006) 115-124
29. Kessler R. The effects of stressful life events on depression. Annu. Rev. Psychol. 48 (1997) 191-214
30. Lappalainen J., Kranzler H.R., Malison R., Price L.H., Van Dyck C., Rosenheck R.A., Cramer J., Southwick S., Charney D., Krystal J., and Gelernter J. A functional neuropeptide Y Leu7Pro polymorphism associated with alcohol dependence in a large population sample from the United States. Arch. Gen. Psychiatry 59 (2002) 825-831
31. Lundberg I., Damström Thakker K., Hällström T., and Forsell Y. Determinants of non-participation, and the effects of non-participation on potential cause-effect relationships, in the PART Study on mental disorders. Soc. Psychiatry Psychiatr. Epidemiol. 40 (2005) 475-483
32. Ma J., Nordman S., Möllsten A., Falhammar H., Brismar K., Dahlquist G., Efendic S., and Gu H.F. Distribution of neuropeptide Y Leu7Pro polymorphism in patients with type 1 diabetes and diabetic nephropathy among Swedish and American populations. Eur. J. Endocrinol. 157 (2007) 641-645
33. Marks I.M., and Mathews A.M. Brief standard self-rating for phobic patients. Behav. Res. Ther. 17 (1979) 263-267
34. Mathé A.A., Jimenez P.A., Theodorsson E., and Stenfors C. Neuropeptide Y, neurokinin A and neurotensin in brain regions of Fawn Hooded "depressed", Wistar, and Sprague Dawley rats. Effects of electroconvulsive stimuli. Prog. Neuro-psychopharmacol. Biol. Psychiatry 22 (1998) 529-546
35. Mikkelsen J.D., Woldbye D., Kragh J., Larsen P.J., and Bolwig T.G. Electroconvulsive shocks increase the expression of neuropeptide Y (NPY) mRNA in the piriform cortex and the dentate gyrus. Brain Res. Mol. Brain Res. 23 (1994) 317-322
36. Nikisch G., Agren H., Eap C.B., Czernik A., Baumann P., and Mathé A.A. Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. Int. J. Neuropsychopharmacol. 8 (2005) 403-410
37. Nilsson C., Karlsson G., Blennow K., Heilig M., and Ekman R. Differences in the neuropeptide Y-like immunoreactivity of the plasma and platelets of human volunteers and depressed patients. Peptides 17 (1996) 359-362
38. Nordman S., Ding B., Ostenson C.G., et al. Leu7Pro polymorphism in the neuropeptide Y (NPY) gene is associated with impaired glucose tolerance and type 2 diabetes in Swedish men. Exp. Clin. Endocrinol. Diabetes 113 (2005) 282-287
39. Painsipp E., Wultsch T., Edelsbrunner M.E., Tasan R.O., Singewald N., Herzog H., and Holzer P. Reduced anxiety-like and depression-related behavior in neuropeptide Y Y4 receptor knockout mice. Genes Brain Behav. 7 (2008) 532-542
40. Pettersson-Fernholm K., Karvonen M.K., Kallio J., et al. FinnDiane Study Group. Leucine 7 to proline 7 polymorphism in the preproneuropeptide Y is associated with proteinuria, coronary heart disease, and glycemic control in type 1 diabetic patients. Diabetes Care 27 (2004) 503-509
41. Pihlajamaki J., Karhapaa P., Vauhkonen I., et al. The Leu7Pro polymorphism of the neuropeptide Y gene regulates free fatty acid metabolism. Metabolism 52 (2003) 643-646
42. Saunders J.B., Aasland O.G., Babor T.F., De La Fuente J.R., and Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption. Addiction 88 (1993) 791-804
43. Sheehan D.V. The anxiety disease. Charles Schribners Sons, NY (1983) 124-129
44. Sjöholm L., Lavebratt C., and Forsell Y. A multifactorial developmental model for the etiology of major depression in a population-based sample. J. Affect. Disord. (2008) Jun 14
45. Sorensen G., Lindberg C., Wortwein G., Bolwig T.G., and Woldbye D.P. Differential roles for neuropeptide Y Y1 and Y5 receptors in anxiety and sedation. J. Neurosci. Res. 77 (2004) 723-729
46. Sperk G., Hamilton T., and Colmers W.F. Neuropeptide Y in the dentate gyrus. Prog. Brain Res. 163 (2007) 285-297
47. Stogner K.A., and Holmes P.V. Neuropeptide-Y exerts antidepressant-like effects in the forced swim test in rats. Eur. J. Pharmacol. 387 (2000) R9-R10
48. Ukkola O., and Kesäniemi Y.A. Leu7Pro polymorphism of PreproNPY associated with an increased risk for type II diabetes in middle-aged subjects. Eur. J. Clin. Nutr. 61 (2007) 1102-1105
49. Undén A.L., and Orth-Gomér K. Development of a social support instrument for use in population surveys. Soc. Sci. Med. 29 (1989) 1387-1392
50. Wahlestedt C., Pich E.M., Koob G.F., Yee F., and Heilig M. Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science 259 (1993) 528-531
51. Westrin A., Ekman R., and Träskman-Bendz L. Alterations of corticotropin releasing hormone (CRH) and neuropeptide Y (NPY) plasma levels in mood disorder patients with a recent suicide attempt. Eur. Neuropsychopharmacol. 9 (1999) 205-211
52. Widdowson P.S., Ordway G.A., and Halaris A.E. Reduced neuropeptide Y concentrations in suicide brain. J. Neurochem. 59 (1992) 73-80
53. Zhou Z., Zhu G., Hariri A.R., Enoch M.A., Scott D., Sinha R., Virkkunen M., Mash D.C., Lipsky R.H., Hu X.Z., Hodgkinson C.A., Xu K., Buzas B., Yuan Q., Shen P.H., Ferrell R.E., Manuck S.B., Brown S.M., Hauger R.L., Stohler C.S., Zubieta J.K., and Goldman D. Genetic variation in human NPY expression affects stress response and emotion. Nature 452 (2008) 997-1001
54. Zhu G., Pollak L., Mottagui-Tabar S., Wahlestedt C., Taubman J., Virkkunen M., Goldman D., and Heilig M. NPY Leu7Pro and alcohol dependence in Finnish and Swedish populations. Alcohol Clin. Exp. Res. 27 (2003) 19-24
55. Zill P., Preuss U.W., Koller G., Bondy B., and Soyka M. Analysis of single nucleotide polymorphisms and haplotypes in the neuropeptide Y gene: no evidence for association with alcoholism in a German population sample. Alcohol Clin. Exp. Res. 32 (2008) 430-434